Nonetheless, clinical trials using TGF-β inhibitors for the treatment of bone metastasis have yielded limited survival benefits and some adverse effects likely arise since TGF-β is so broadly expressed throughout the body. This evidence concerns the gene TGFB1 and bone metastasis.